All of the major dermal fillers either have lidocaine already or will soon have it, so AGN’s FDA approval of Juvederm with lidocaine was important from a competitive standpoint.
-- p.s. Merz’s acquisition of BFRM closes this week. Here’s a question to ponder: Will Merz now become a buyout target in its own right? I originally thought JNJ would end up owning BFRM at some point and they still could—by buying Merz.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.